{"id":553060,"date":"2021-07-15T18:12:01","date_gmt":"2021-07-15T18:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=553060"},"modified":"2021-07-15T18:12:01","modified_gmt":"2021-07-15T18:12:01","slug":"follicular-lymphoma-market-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/follicular-lymphoma-market-epidemiology-and-market-forecast-2030_553060.html","title":{"rendered":"Follicular Lymphoma Market, Epidemiology, and Market Forecast \u2013 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Follicular Lymphoma Market, Epidemiology, and Market Forecast &ndash; 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Follicular Lymphoma Market, Epidemiology, and Market Forecast &ndash; 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast \u2013 2030\u2019 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. <\/p>\n<\/div>\n<p style=\"text-align: justify;\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/bisouv.com\/wp-content\/uploads\/2021\/06\/Follicular-Lymphoma-Market.jpg\" alt=\"Follicular-Lymphoma-Market\" width=\"560\" height=\"306\" \/><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &lsquo;Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast &ndash; 2030&rsquo; report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><span>What is Follicular Lymphoma?<\/span><\/p>\n<p style=\"text-align: justify;\">Follicular lymphoma, a B-cell lymphoma, is the second most common type of low-grade non-Hodgkin lymphoma (NHL). The transformation of a B-cell characterizes it into a malignant cell. Abnormal, uncontrolled growth and proliferation of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs.<\/p>\n<p style=\"text-align: justify;\"><span>&nbsp;What are Follicular Lymphoma causes?<\/span><\/p>\n<p style=\"text-align: justify;\">Follicular Lymphoma causes are not known. Unlike some cancers, they are not passed down in families. In some cases, radiation or cancer-causing chemicals, or certain infections, may be a cause. But other times there is no known cause.<\/p>\n<p style=\"text-align: justify;\"><span>What are the symptoms of Follicular Lymphoma?<\/span><\/p>\n<p style=\"text-align: justify;\">Follicular Lymphoma symptoms include painless swelling of the lymph nodes in your neck, groin, stomach, or armpits, shortness of breath, fatigue, night sweats, and weight loss.<\/p>\n<p style=\"text-align: justify;\"><span>How Follicular Lymphoma affected population?<\/span><\/p>\n<p style=\"text-align: justify;\"><span>Follicular Lymphoma Epidemiology<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>According to DelveInsight&rsquo;s analysis, the total prevalent population of Follicular Lymphoma in seven major markets was&nbsp;<span>33,363<\/span>&nbsp;in 2017. These cases are expected to increase with a significant CAGR during the study period (2017&ndash;2030).<\/li>\n<li>Among all the seven major markets, the United States accounts for the highest number of Follicular Lymphoma cases<span>.<\/span><\/li>\n<li>In the US, the Follicular Lymphoma cases were&nbsp;<span>14,329&nbsp;<\/span>in 2017. Moreover, the grade-specific cases of Follicular Lymphoma were highest among grade I and were reported to be 5,198 cases.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">To know more, request sample pages @<a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights?utm_source=satpr&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" ><span>Follicular Lymphoma Market Landscape<\/span><\/a><\/p>\n<p style=\"text-align: justify;\"><span>Follicular Lymphoma Market Outlook<\/span><\/p>\n<p style=\"text-align: justify;\">According to DelveInsight, the&nbsp;<a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=satpr&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" ><span>Follicular Lymphoma market size<\/span><\/a>&nbsp;is expected to increase at a significant CAGR during the study period (2017&ndash;2030). Among all the seven major markets, the United States accounts for the largest Follicular Lymphoma market size with&nbsp;<span>USD 799 million<\/span>&nbsp;in 2017, while Spain had the smallest market size of Follicular Lymphoma with&nbsp;<span>USD 56 million<\/span>&nbsp;in 2017<span>.<\/span><\/p>\n<p style=\"text-align: justify;\"><span>What are the present Follicular Lymphoma market drivers?<\/span><\/p>\n<p style=\"text-align: justify;\">Changing standards of care, increasing opportunities and family history aims at driving the market growth.<\/p>\n<p style=\"text-align: justify;\"><span>What are the Follicular Lymphoma market barriers?<\/span><\/p>\n<p style=\"text-align: justify;\">Clinical heterogeneity, economic burden of the disease and adverse effects of the therapies are some limitations to the&nbsp;<a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=satpr&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" ><span>Follicular Lymphoma Market Growth<\/span><\/a>.<\/p>\n<p style=\"text-align: justify;\"><span>Which are the leading companies in Follicular Lymphoma market?<\/span><\/p>\n<p style=\"text-align: justify;\">Key Players such as Epizyme, Kite Pharma, Novartis, Roche, Regeneron, TG therapeutics, MEI Pharma, Incyte Corporation, Bayer Health, Verastem Oncology, Gilead Sciences, Xynomics Pharmaceuticals, Bristol Myeres, Takeda Oncology, and others are the leading companies in Follicular Lymphoma market.<\/p>\n<p style=\"text-align: justify;\">Request sample pages for more information on&nbsp;<a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights?utm_source=satpr&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" ><span>Follicular Lymphoma Market Size<\/span><\/a><\/p>\n<p style=\"text-align: justify;\"><span>Table of contents<\/span><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Follicular Lymphoma<\/p>\n<p style=\"text-align: justify;\">3. SWOT Analysis for Follicular Lymphoma<\/p>\n<p style=\"text-align: justify;\">4. Follicular Lymphoma Market Overview at a Glance<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Market Share (%) Distribution of Follicular Lymphoma in 2018<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Market Share (%) Distribution of Follicular Lymphoma in 2030<\/p>\n<p style=\"text-align: justify;\">5. Disease Background and Overview<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2. Types of Follicular Lymphoma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.3. Sign and Symptoms<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.4. Causes<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.5. Staging and Grading<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.6. Genetic Landscape of Follicular Lymphoma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.7. Pathophysiology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.8. Diagnosis<\/p>\n<p style=\"text-align: justify;\">6. Epidemiology and Patient Population<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.2. 7MM Total Incident Patient Population of Follicular Lymphoma<\/p>\n<p style=\"text-align: justify;\">7. Country Wise-Epidemiology of Follicular Lymphoma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Assumptions and Rationale &ndash; 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. The United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.2.1. Total Incident Cases of Follicular Lymphoma in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.2.2. Grade-specific Cases of Follicular Lymphoma in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.2.3. Age-specific Cases of Follicular Lymphoma in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.2.4. Stage-specific Cases of Follicular Lymphoma in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. EU5<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.1. Germany<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.1.1. Total Incident Cases of Follicular Lymphoma in Germany<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.1.2. Grade-specific Cases of Follicular Lymphoma in Germany<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.1.3. Age-specific Cases of Follicular Lymphoma in Germany<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.1.4. Stage-specific Cases of Follicular Lymphoma in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.2. France<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.2.1. Total Incident Cases of Follicular Lymphoma in France<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.2.2. Grade-specific Cases of Follicular Lymphoma in France<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.2.3. Age-specific Cases of Follicular Lymphoma in France<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.2.4. Stage-specific Cases of Follicular Lymphoma in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.3. Italy<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.3.1. Total Incident Cases of Follicular Lymphoma in Italy<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.3.2. Grade-specific Cases of Follicular Lymphoma in Italy<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.3.3. Age-specific Cases of Follicular Lymphoma in Italy<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.3.4. Stage-specific Cases of Follicular Lymphoma in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.4. Spain<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.4.1. Total Incident Cases of Follicular Lymphoma in Spain<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.4.2. Grade-specific Cases of Follicular Lymphoma in Spain<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.4.3. Age-specific Cases of Follicular Lymphoma in Spain<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.4.4. Stage-specific Cases of Follicular Lymphoma in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.5. The United Kingdom<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.5.1. Total Incident Cases of Follicular Lymphoma in the United Kingdom<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.5.2. Grade-specific Cases of Follicular Lymphoma in the United Kingdom<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.5.3. Age-specific Cases of Follicular Lymphoma in the UK<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.3.5.4. Stage-specific Cases of Follicular Lymphoma in the UK<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.1. Total Incident Cases of Follicular Lymphoma in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.2. Grade-specific Cases of Follicular Lymphoma in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.3. Age-specific Cases of Follicular Lymphoma in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.4. Stage-specific Cases of Follicular Lymphoma in Japan<\/p>\n<p style=\"text-align: justify;\">8. Treatment<\/p>\n<p style=\"text-align: justify;\">9. Guidelines<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.1. NCCN Guidelines for Patient with Follicular Lymphoma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.2. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: Newly diagnosed and relapsed follicular lymphoma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.3. Japanese Society of Hematology (JSH) practical guidelines for Follicular lymphoma<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Organizations contributing toward Follicular Lymphoma<\/p>\n<p style=\"text-align: justify;\">12. Patient Journey<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1. A Journey through follicular lymphoma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2. Patient Journey: General<\/p>\n<p style=\"text-align: justify;\">13. Case Reports<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Patient Case Study: From Follicular Lymphoma to DLBCL<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2. Diagnostic Workup for Follicular Lymphoma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3. A case study of t(14;22)(q32;q11) involving immunoglobulin heavy and light chain in follicular lymphoma<\/p>\n<p style=\"text-align: justify;\">14. Marketed Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.1. Tazverik: Epizyme<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.2. Aliqopa: Bayer Healthcare Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.3. Copiktra: Verastem Oncology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.4. Zydelig: Gilead Sciences<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.4. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">15. Combinational Therapies: Marketed<\/p>\n<p style=\"text-align: justify;\">16. Emerging Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1. Abexinostat: Xynomic Pharmaceuticals, Inc.<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.1.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.1.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.1.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.1.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2. Umbralisib: TG Therapeutics<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.2.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.3. ME-401: MEI Pharma<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.3.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.3.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.3.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.3.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.4. Odronextamab: Regeneron Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.4.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.4.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.4.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.4.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.5. Parsaclisib: Incyte Corporation<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.5.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.5.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.5.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.5.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.6. Kymriah: Novartis<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.6.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.6.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.6.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.7. Yescarta: Kite Pharma<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.7.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.7.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.7.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.7.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.8. Nivolumab: Bristol-Myers Squibb<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.8.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.8.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.8.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.8.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.9. Ixazomib &ndash; Takeda Oncology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.9.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.9.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.9.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.9.4. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">17. Emerging Combinational Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.1. Ibrutinib + Rituximab<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.2. Umbralisib + Ublituximab + Bendamustine<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.3. Zanubrutinib + Obinutuzumab<\/p>\n<p style=\"text-align: justify;\">18. Other Promising Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.1. Atezolizumab: Roche<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.1.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.1.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.1.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.1.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.2. Pembrolizumab: Merck<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.3. Venetoclax &ndash; AbbVie\/Genentech<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.3.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.3.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.3.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.3.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.4. Betalutin: Nordic Nanovector ASA<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.5. Tenalisib: Rhizen Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.5.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.5.2. Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.5.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.5.4. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">19. Follicular Lymphoma: Seven Major Market Analysis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.2. Market Size of Follicular Lymphoma in 7MM<\/p>\n<p style=\"text-align: justify;\">20. Market Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1. 7MM Market Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2. United States Market Size<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.3. EU-5 Countries: Market Outlook<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.3.1. Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.3.2. France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.3.3. Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.3.4. Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.3.5. United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.4. Japan: Market Outlook<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.4.1. Total Market Size of Follicular Lymphoma<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.4.2. Market Size of Follicular Lymphoma by Therapies<\/p>\n<p style=\"text-align: justify;\">21. Market Drivers<\/p>\n<p style=\"text-align: justify;\">22. Market Barriers<\/p>\n<p style=\"text-align: justify;\">23. Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">24. Appendix<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\">25. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">26. Disclaimer<\/p>\n<p style=\"text-align: justify;\">27. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=follicular-lymphoma-market-epidemiology-and-market-forecast-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=follicular-lymphoma-market-epidemiology-and-market-forecast-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast \u2013 2030\u2019 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/follicular-lymphoma-market-epidemiology-and-market-forecast-2030_553060.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-553060","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=553060"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553060\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=553060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=553060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=553060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}